A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > ORGANIZATION
ORGANIZATION
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
- JPMA Reiterates It’s Not the Right Time for Off-Year Drug Price Survey
July 17, 2020
- Number of Contract Sales Reps Up 10.8% to 3,445, with New Drug Launches
July 17, 2020
- JMA Chief Says Off-Year Price Survey “Technically Impossible”, JPA President Meets PM
July 16, 2020
- Japan Red Cross Presses ahead with Joint Purchase of Drugs Selected under Formularies at Group Hospitals
July 15, 2020
- AMR Action Fund Would Help Deal with Threat While We Still Have Time: IFPMA Vice Pres.
July 14, 2020
- JMA Reiterates Concerns for Off-Year Drug Price Survey after Govt’s Honebuto Draft Revealed
July 13, 2020
- Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
- COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
- Generic Use Rate at 76.9% in FY2019, 78.5% in Jan.-March 2020: JGA
July 1, 2020
- Toshio Nakagawa Elected as New Chief of Japan Medical Association
June 29, 2020
- JPMA to Govt: Build Japanese CDC to Run Infectious Disease Measures, Pandemics Will Certainly Hit Again
June 18, 2020
- It’s Not the Right Time to Conduct Drug Price Survey for Off-Year Re-Pricing: JPMA Chief
June 18, 2020
- Japan Biotech Group Submits Request to Health Minister on Coronavirus-Tied Development
June 17, 2020
- Nearly 80% of Clinics See Increase in Long-Term Prescriptions amid COVID-19: JMA Survey
June 15, 2020
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…